82 completed, 9 unknown, 7 terminated, 5 active not recruiting. 115 Phase 2, 17 Phase 1, 10 Phase 3.
Follow Keratosis: new trials by email Literature Review of Keratosis trials Research Report on Keratosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| PDT vs Peels for Treatment of Actinic Keratoses Photodynamic Therapy, Chemical Peels - Actinic Keratoses | Phase 2 | Not yet recruiting | Northwestern University | 60 | 2026-08-01 | 2026-07-01 |
| A Phase 2 Study of HW211026 HW211026 - Actinic Keratosis | Phase 2 | Not yet recruiting | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | 80 | 2026-07-01 | 2026-07-09 |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Evaluate RLS-1496 Topical Cream for Actinic Keratosis RLS-1496 1.0% cream - Actinic Keratosis (AK) | Phase 1 / Phase 2 | Active not recruiting | Rubedo Life Sciences, Inc. | 24 | 2026-02-03 | 2026-08-12 |
| Immunotherapy After Transplantation for Skin Cancer Prevention in Organ Transplant Recipients Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU - Immunotherapy, Cutaneous Squamous Cell Carcinoma | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2025-05-07 | |
| Immunotherapy Before Transplantation for Skin Cancer Prevention in Organ Transplant Recipients Calcipotriol Only Product in Cutaneous Dose Form, Vaseline, Topical 5FU - Cutaneous Squamous Cell Carcinoma, Actinic Keratoses | Phase 2 | Withdrawn | Massachusetts General Hospital | 2026-01-01 | 2025-05-07 | |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| The Effect of Topical Imipramine on Photodynamic Therapy-Mediated Immunosuppression on Forearms or Face on US Veterans Imipramine, Control Vehicle - Actinic Keratosis, Imipramine | Phase 2 | Recruiting | VA Office of Research and Development | 48 | 2025-04-01 | 2025-12-22 |
| Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratoderma Tapinarof - Palmoplantar Keratoderma | Phase 2 | Active not recruiting | Indiana University | 6 | 2024-10-30 | 2026-06-23 |
| Efficacy of Injectable Gentamicin in Hereditary Ichthyosis Gentamicin Injectable Solution - Ichthyosis | Phase 2 | Not yet recruiting | University Hospital, Toulouse | 26 | 2024-09-01 | 2024-09-05 |
| Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses Topical Aminolevulinate, Photodynamic therapy (PDT), Red light illumination - Actinic Keratoses | Phase 2 | Completed | Case Comprehensive Cancer Center | 14 | 2024-08-25 | 2026-02-20 |
| Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients Biopsy, Calcipotriene, Fluorouracil - Actinic Keratosis | Phase 2 | Active not recruiting | University of Arizona | 56 | 2024-07-02 | 2025-09-24 |
| Comparison of Rimegepant and Placebo for Pain in IBS Rimegepant 75 MG [Nurtec] - Irritable Bowel Syndrome | Phase 2 | Completed | Mayo Clinic | 39 | 2024-06-06 | 2026-10-15 |
| Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis Bimiralisib - Actinic Keratosis | Phase 2 | Completed | TORQUR | 46 | 2024-04-02 | 2025-07-18 |
| A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses deucravacitinib - Epidermolysis Bullosa Simplex, Ichthyosis | Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2024-03-18 | 2026-10-16 |
| A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis SM-020 gel 1.0%, Vehicle gel - Seborrheic Keratosis | Phase 2 | Unknown | DermBiont, Inc. | 60 | 2023-11-06 | 2024-05-10 |
| Short Contact Protocols to Reduce Pain During 10% ALA Gel Red-light Photodynamic Therapy of Actinic Keratoses Topical aminolevulinate (10% ALA gel), Red light illumination - Actinic Keratosis | Phase 2 | Completed | Case Comprehensive Cancer Center | 30 | 2023-10-02 | 2025-10-23 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
Showing 20 of 115. Sign in to see all of them.
Keratosis, Actinic (74) · Netherton Syndrome (11) · Keratosis, Seborrheic (7) · Ichthyosis (6) · Carcinoma, Basal Cell (5) · Carcinoma, Squamous Cell (5) · Precancerous Conditions (5) · Skin Neoplasms (5) · Ichthyosis Bullosa of Siemens (4) · Callosities (3) · Ichthyosis Vulgaris (3) · Ichthyosis, Lamellar (3) · Ichthyosis, X-Linked (3) · Irritable Bowel Syndrome (3)
Skin Diseases (115) · Skin and Connective Tissue Diseases (115) · Neoplasms (76) · Precancerous Conditions (69) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (30) · Congenital Abnormalities (29) · Skin Abnormalities (29) · Genetic Diseases, Inborn (28) · Skin Diseases, Genetic (27) · Infant, Newborn, Diseases (26) · Ichthyosis (23) · Ichthyosiform Erythroderma, Congenital (13) · Abnormalities, Multiple (12) · Neoplasms by Histologic Type (12)
Aminolevulinic Acid (11) · 3-ingenyl angelate (10) · Photochemotherapy (6) · Fluorouracil (5) · Imiquimod (5) · N-phenylacetoaminomethylene-DL-p-nitrophenylalanine (4) · Petrolatum (4) · Gels (3) · LEO 43204 (3) · Solutions (3) · 1-phenyl-3,3-dimethyltriazene (2) · Cryotherapy (2) · Doxorubicin (2) · Isotretinoin (2) · SR-T100 (2)
LEO Pharma (8) · Peplin (8) · DUSA Pharmaceuticals, Inc. (7) · Aclaris Therapeutics, Inc. (4) · Quoin Pharmaceuticals (4) · Almirall, S.A. (3) · Case Comprehensive Cancer Center (3) · Mayo Clinic (3) · Northwestern University (3) · University of Arizona (3) · Bispebjerg Hospital (2) · DermBiont, Inc. (2) · G&E Herbal Biotechnology Co., LTD (2) · Icahn School of Medicine at Mount Sinai (2) · Massachusetts General Hospital (2)
United States (70) · Germany (14) · France (10) · Australia (9) · Canada (6) · Denmark (5) · Italy (4) · Switzerland (4) · United Kingdom (4) · Belgium (3) · Israel (3) · Netherlands (3) · Sweden (3) · Austria (2) · Brazil (2)
Stuart Marcus, MD, PhD (6) · Gary Goldenberg, MD (2) · Janet Dubois, MD (2) · Shadmehr Demehri, MD/PHD (2) · Tony Andrasfay (2) · Albert C Yan, MD (1) · Amy Paller (1) · Amy Paller, MD (1) · Andres Poveda, Ph.M. (1) · Andrew Blauvelt, MD, MBA (1) · Anjali Shroff, MD (1) · Arthur P Bertolino, MD (1) · Brian Beger, BS (1) · C. William Hanke, MD (1) · Chaim M Brickman, MD (1)
PMID 38125671, PMID 11493098, PMID 20083693, PMID 20691689, PMID 21115882, PMID 22517769, PMID 22934545, PMID 24068130, PMID 24102348, PMID 25124939, PMID 25257941, PMID 25584134, PMID 26011755, PMID 26054651, PMID 28264612, PMID 29399258, PMID 29399263, PMID 31299087, PMID 31915160, PMID 33196758, PMID 35218370, PMID 35314199, PMID 36198452, PMID 37170057, PMID 40047786, PMID 40581198, PMID 41637861
P01CA027502 (2), P30CA023074 (2), UL1RR024150 (2), 1RC1DK086182 (1), 2008 (1), 2014 (1), 2015 (1), R01DK054681 (1), R01DK079866 (1), R44CA250727 (1), UG1CA242596 (1)